GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » ROE %

Aarti Drugs (BOM:524348) ROE % : 14.77% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Aarti Drugs's annualized net income for the quarter that ended in Mar. 2024 was ₹1,892 Mil. Aarti Drugs's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ₹12,816 Mil. Therefore, Aarti Drugs's annualized ROE % for the quarter that ended in Mar. 2024 was 14.77%.

The historical rank and industry rank for Aarti Drugs's ROE % or its related term are showing as below:

BOM:524348' s ROE % Range Over the Past 10 Years
Min: 13.86   Med: 21.01   Max: 35.81
Current: 13.96

During the past 13 years, Aarti Drugs's highest ROE % was 35.81%. The lowest was 13.86%. And the median was 21.01%.

BOM:524348's ROE % is ranked better than
79.14% of 997 companies
in the Drug Manufacturers industry
Industry Median: 4.25 vs BOM:524348: 13.96

Aarti Drugs ROE % Historical Data

The historical data trend for Aarti Drugs's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs ROE % Chart

Aarti Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.65 35.81 21.03 14.92 13.86

Aarti Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.82 16.05 13.09 12.13 14.77

Competitive Comparison of Aarti Drugs's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's ROE % distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's ROE % falls into.



Aarti Drugs ROE % Calculation

Aarti Drugs's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=1714.2/( (11924.347+12815.6)/ 2 )
=1714.2/12369.9735
=13.86 %

Aarti Drugs's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=1892.4/( (0+12815.6)/ 1 )
=1892.4/12815.6
=14.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Aarti Drugs  (BOM:524348) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=1892.4/12815.6
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1892.4 / 24799.6)*(24799.6 / 24323.6)*(24323.6 / 12815.6)
=Net Margin %*Asset Turnover*Equity Multiplier
=7.63 %*1.0196*1.898
=ROA %*Equity Multiplier
=7.78 %*1.898
=14.77 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=1892.4/12815.6
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (1892.4 / 2567.2) * (2567.2 / 2888.8) * (2888.8 / 24799.6) * (24799.6 / 24323.6) * (24323.6 / 12815.6)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7371 * 0.8887 * 11.65 % * 1.0196 * 1.898
=14.77 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Aarti Drugs ROE % Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs (BOM:524348) Business Description

Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400 022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm generates the majority of its revenue from India.

Aarti Drugs (BOM:524348) Headlines

No Headlines